At the news
? BULLISHIMPACT 5/10 COURT-RULING filed May 18, 2026 at 20:00 ET
The Federal Circuit reversed the district court's dismissal of Medtronic Ireland's patent infringement counterclaims against Recor Medical, ruling that Medtronic retained constitutional standing due to its retained right to sue, royalty interests, and veto power over sublicenses. This procedural victory allows Medtronic to continue enforcing its renal denervation patents (U.S. 8,845,629 and 11,801,085) against Recor's competing Paradise System, with the case remanded for joinder consideration.
- Federal Circuit reversed district court's dismissal for lack of standing, holding Medtronic Ireland retained exclusionary rights (right to sue, royalties, sublicense veto).
- Ruling based on precedential opinion A.L.M. Holding Co. v. Zydex, finding Medtronic's retained rights materially similar.
- Case remanded for determination of whether Medtronic Galway should be joined as necessary party for statutory standing.
- Patents cover renal neuromodulation technology used in Medtronic's Symplicity Spyral RDN system; Recor's Paradise System is a direct competitor.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access